kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human B7-H4, ultra sensitivity (primary amine labeling), 25µg  

Recombinant Biotinylated Human B7-H4, ultra sensitivity (primary amine labeling), 25µg

MABSol® Recombinant Biotinylated Human B7-H4 Protein, expressed from human HEK293 cells, His Tag, ultra sensitivity (primary amine labeling)

recombinant, human, biotinylated, protein, B7-H4,VTCN1,B7S1,B7h.5

More details


Availability: within 7 days

377,00 €

V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

MABSol® Recombinant Biotinylated Human B7-H4, His Tag, primary amine labeling (B74-H8222) is expressed from human HEK293 cells. It contains AA Phe 29 - Ala 258 (Accession # NP_078902). It is the biotinylated form of Human B7-H4, His Tag (Cat. No. B74-H5222).
Predicted N-terminus: Phe 29

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.4 kDa. The protein migrates as 43-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.

Biotin:Protein Ratio
The biotin to protein ratio is 3-5 as determined by the HABA assay.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Please refer to product data sheet.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Chronic LCMV infection regulates the effector T cell response by inducing the generation of less immunogenic dendritic cells"
Yoo, Jeong, Choi et al
Exp Mol Med (2023)
(2) "Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies"
Pulanco, Madsen, Tanwar et al
Cell Mol Immunol (2023)
(3) "Association of B7H3 and B7H4 gene polymorphisms and protein expression with the development and prognosis of autoimmune thyroid diseases"
Ozaki, Inoue, Iwatani et al
Clin Endocrinol (Oxf) (2023)
Showing 1-3 of 453 papers.